Author： Galsky Matthew D. Pal Sumanta K. Chowdhury Simon Harshman Lauren C. Crabb Simon J. Wong Yu-Ning Yu Evan Y. Powles Thomas Moshier Erin L. Ladoire Sylvain Hussain Syed A. Agarwal Neeraj Vaishampayan Ulka N. Recine Federica Berthold Dominik Necchi Andrea Theodore Christine Milowsky Matthew I. Bellmunt Joaquim Rosenberg Jonathan E. Galsky Matthew D.
Publisher： Blackwell Publishing
E-ISSN： 1097-0142|121|15|2586-2593
ISSN： 0008-543X
Source： Cancer, Vol.121, Iss.15, 2015-08, pp. : 2586-2593
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Gemcitabine plus cisplatin for NSCLC
Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. :
Access to resources
Recommend
Gemcitabine plus cisplatin an option in urothelial cancer?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 284, 2000-01 ,pp. :
By Liubao Peng
PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. :
Combination gemcitabine + cisplatin therapy for recurrent ovarian cancer
Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. :
By Mermershtain Wilmosh Neumann Avivit Gusakova Irina Yusim Igor Neulander Endre Lavrenkov Konstantin
UroOncology, Vol. 3, Iss. 1, 2003-01 ,pp. :